TAOK1 regulates chemo- and radiosensitivity in BRCA1/2-deficient tumors
Authors:
- Lea LinggLLLea Lingg
- Merve MutluMMMerve Mutlu
- Arunasalam NaguleswaranANArunasalam Naguleswaran
- Ismar KlebicIKIsmar Klebic
- Ewa GogolaEGEwa Gogola
- Dilara Akhoundova SanoyanDSDilara Akhoundova Sanoyan
- Pascale Martine SchürchPSPascale Martine Schürch
- Raviprasad KuthethurRKRaviprasad Kuthethur
- Carmen FonsecaCFCarmen Fonseca
- Simone de BrotSBSimone de Brot
- Marieke EvertsMEMarieke Everts
- Martín González-FernándezMGMartín González-Fernández
Preprint
Abstract
BRCA1/2-deficient cells are hypersensitive to replication stress- and DNA-damage-inducing agents such as poly(ADP-ribose) polymerase inhibitors (PARPi), platinum drugs, and ionizing radiation (IR), largely due to impaired homologous recombination repair and replication fork (RF) protection. The precise mechanisms underlying RF vulnerability in the absence of BRCA1/2 remain incompletely understood, however. Here, we identify Thousand And One Amino Acid Kinase 1 (TAOK1) as a novel regulator of RF dynamics that sensitizes BRCA1/2-deficient cells to both PARPi and IR. Unlike established DNA repair factors, such as PARG or the 53BP1-RIF1-shieldin-CST pathway, which mediate PARPi sensitivity while protecting cells against IR, TAOK1 promotes RF degradation and suppresses post-replicative damage repair. TAOK1 depletion stabilizes RFs and reduces replication-associated DNA damage in BRCA1/2-deficient cells, thereby conferring therapy resistance. Interestingly, we found that TAOK1 functions in RF regulation to be independent of its kinase activity. Instead, it interacts with PCNA and regulates ISG15 levels and thereby affects RF stability. Our findings reveal TAOK1 as a non-canonical mediator of therapy sensitivity in BRCA1/2-deficient tumors. Teaser: TAOK1 controls replication fork stability through PCNA and ISG15, affecting therapy response in BRCA1/2-deficient cancers.Keywords
Funding Information
- Swiss National Science Foundation (grant 320030M_219453 (JJ, SR))
- European Research Council (grant ERC-2019-AdG-883877 (SR))
- Swiss Cancer Research Foundation (grant KFS-5519-02-2022 (SR))
- Office of the Assistant Secretary of Defense for Health Affairs through the Ovarian Cancer Research Program (Award No. W81XWH-22-1-0557 (SR))
- ISREC Foundation grant ((SR))
- Foundation for Clinical-Experimental Cancer Research ((PF))
This publication has 68 references indexed in Scilit:
- Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumorsCell Reports, 2023
- The Hippo Signaling Pathway in Development and DiseaseDevelopmental Cell, 2019
- De Novo Variants in TAOK1 Cause Neurodevelopmental DisordersThe American Journal of Human Genetics, 2019
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic LethalityCancer Cell, 2018
- The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient CellsCell Reports, 2018
- DNA Fiber Analysis: Mind the Gap!2017
- A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2Cancer Cell, 2012
- The Sterile 20-like Kinase Tao-1 Controls Tissue Growth by Regulating the Salvador-Warts-Hippo PathwayDevelopmental Cell, 2011
- Tao-1 Phosphorylates Hippo/MST Kinases to Regulate the Hippo-Salvador-Warts Tumor Suppressor PathwayDevelopmental Cell, 2011
- Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11Cell, 2011